imc-cs4
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01346358)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109323 ↗
Also known as
- imc-cs4
- imc-cs4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03153410 | Early Phase 1 (Phase 1) | Sep 1, 2017 | Eli Lilly, Johns Hopkins University, Merck |
| NCT01346358 | Phase 1 | Jun 1, 2011 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 1 | 1 | 2011 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1